Pharmacokinetic/pharmacodynamic assessment of the in-vivo efficacy of imipenem alone or in combination with amikacin for the treatment of experimental multiresistant Acinetobacter baumannii pneumonia

Clinical Microbiology and Infection

Volumn 11, Issue 4, 2005, Pages 319-325

  Bernabeu Wittel, M ^a   Pichardo, C ^a   Garcia Curiel A ^a   Pachon Ibanez M E ^a   Ibanez Martinez J ^b   Jimenez Mejias M E ^a   Pachon J ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

Author keywords

Acinetobacter baumannii; Amikacin; Experimental pneumonia; Impenem; Pharmacodynamics; Pharmacokinetics

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; AZTREONAM; CARBAPENEM DERIVATIVE; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; NETILMICIN; OFLOXACIN; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; TICARCILLIN; TOBRAMYCIN;

ACINETOBACTER BAUMANNII; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL COUNT; BACTERIAL PNEUMONIA; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BIOASSAY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENTIATION; ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE; EXPERIMENTAL INFECTION; FEMALE; GUINEA PIG; IN VITRO STUDY; IN VIVO STUDY; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MULTIDRUG RESISTANCE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL;

ACINETOBACTER BAUMANNII; BACTERIA (MICROORGANISMS); CAVIA PORCELLUS; SUS SCROFA;

EID: 15944414245     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2005.01095.x     Document Type: Article

References (38)

1. Bergogne-Bérézin E, Towner KJ. Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin Microbiol Rev 1996; 9: 148-165.
2. Wendt C, Dietze B, Dietz E, Ruden H. Survival of Acinetobacter baumannii on dry surfaces. J Clin Microbiol 1997; 35: 1394-1397.
3. Torres A, Aznar R, Gatell JM et al. Incidence risk and prognosis factors of nosocomial pneumonia in mechanically ventilated patients. Am Rev Respir Dis 1990; 142: 522-528.
4. Lortholary O, Fagon JY, Hoi AB et al. Nosocomial acquisition of multiresistant Acinetobacter baumannii: risk factors and prognosis. Clin Infect Dis 1995; 20: 790-796.
5. Cisneros JM, Reyes MJ, Pachón J et al. Bacteremia due to Acinetobacter baumannii: epidemiology, clinical findings, and prognostic features. Clin Infect Dis 1996; 22: 1026-1032.
6. Fagon JY, Chastre J, Hance AJ, Montravers P, Novara A, Gibert C. Nosocomial pneumonia in ventilated patients: a cohort study evaluating attributable mortality and hospital stay. Am J Med 1993; 94: 281-288.
7. Allan JD, Moellering RC. Management of infections caused by gram-negative bacilli: the role of antimicrobial combinations. Rev Infect Dis 1985; 7: 559-571.
8. Giamarellou H. Aminoglycosides plus beta-lactams against gram-negative organisms. Evaluation of in vitro synergy and chemical interactions. Am J Med 1986; 80: 126-137.
9. Vila J, Marcos A, Marco F et al. In vitro antimicrobial production of β-lactamases, aminoglycoside-modifying enzymes, and chloramphenicol acetyltransferase by and susceptibility of clinical isolates of Acinetobacter baumannii. Antimicrob Agents Chemother 1993; 37: 138-141.
10. Seifert H, Strate A, Pulverer G. Nosocomial bacteremia due to Acinetobacter baumannii. Clinical features, epidemiology, and predictors of mortality. Medicine (Baltimore) 1995; 74: 340-349.
11. Manikal VM, Landman D, Saurina G, Elyse O, Lal H, Quale J. Endemic carbapenem-resistant Acinetobacter species in Brooklyn, New York: citywide prevalence, interinstitutional spread, and relation to antibiotic usage. Clin Infect Dis 2000; 31: 101-106.
12. Bou G, Cerveró G, Domínguez MA, Quereda C, Martinez Beltran J. Characterization of a nosocomial outbreak caused by a multiresistant Acinetobacter baumannii strain with a carbapenem-hydrolyzing enzyme: high level carbapenem resistance in A. baumannii is not due solely to the presence of β-lactamases. Antimicrob Agents Chemother 2000; 38: 3299-3305.
13. Bouvet PJ, Grimont PAD. Taxonomy of the genus Acinetobacter with the recognition of Acinetobacter baumannii sp. nov., Acinetobacter haemolyticus sp. nov., Acinetobacter johnsonii sp. nov., and Acinetobacter junii sp. nov. and emended descriptions of Acinetobacter calcoaceticus and Acinetobacter lwoffi. Int J Syst Bacteriol 1986; 36: 228-240.
14. Edberg SC, Barry AL, Young LS. Therapeutic drug monitoring: antimicrobial agents. In: Morello JA, ed. Cumulative techniques and procedures in clinical microbiology. Washington, DC: American Society for Microbiology, 1984; 1-20.
15. Thomson SG, Burd JF. Substrate-labeled fluorescent immunoassay for amikacin in human serum. Antimicrob Agents Chemother 1980; 18: 264-268.
16. Edberg SC, Bottenbley CJ, Gam K. Use of sodium polyanethol sulphonate to selectively inhibit aminoglycoside and polymyxin antibiotics in a rapid blood level antibiotic assay. Antimicrob Agents Chemother 1976; 9: 414-417.
17. Schumaker RC. PKCALC: a basic interactive computer program for statistical and pharmacokinetic analysis of data. Drug Metab Rev 1986; 17: 331-348.
18. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26: 1-12.
19. Frimodt-Möller N, Bentzon MW, Thomsen VF. Experimental infection with Streptococcus pneumoniae in mice: correlation of in vitro activity and pharmacokinetic parameters with in vivo effect for 14 cephalosporins. J Infect Dis 1986; 154: 511-517.
20. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically, 5th edn. Approved standards document M7-A5. Wayne, PA: NCCLS, 2000.
21. National Committee for Clinical Laboratory Standards. Methods for determining bactericidal activity of antimicrobial agents. Tentative guideline 771 E. Villanova, PA: NCCLS, 1992.
22. Moody JA. Synergism testing: broth microdilution checkerboard and broth macrodilution methods. In: Isenberg HD, ed. Clinical microbiology procedures handbook. Washington, DC: American Society for Microbiology, 1992; 1-28.
23. Pennington JE. Use of animal model to evaluate antimicrobial therapy for bacterial pneumonia. In: Zak O, Sande MA, eds. Experimental models in antimicrobial chemotherapy. London: Academic Press, 1986; 237-256.
24. Rodríguez-Hernández MJ, Pachón J, Pichardo C et al. Imipenem, doxycycline and amikacin in monotherapy and in combination in Acinetobacter baumanni experimental pneumonia. J Antimicrob Chemother 2000; 45: 493-501.
25. Norrby SR. Carbapenems. Med Clin North Am 1995; 79 745-759.
26. Cuberos L, Rodríguez MJ, Pichardo C et al. Efficacy of imipenem, sulbactam, colistin, and amikacin in experimental endocarditis caused by Acinetobacter baumannii with intermediate susceptibility to imipenem. Clin Microbiol Infect 1999; 5 suppl 3): 341.
27. Riff LJ, Thomason JL. Comparative aminoglycoside inactivation by beta-lactam antibiotics. Effects of a cephalosporin and six penicillins on five aminoglycosides. J Antibiot 1982; 35: 850-857.
28. Wallace SM, Chan LY. In vitro interaction of aminoglycosides with beta-lactam penicillins. Antimicrob Agents Chemother 1985; 28: 274-281.
29. Plantier J, Forrey AW, O'Neill MA, Blair AD, Christopher TG, Cutler RE. Pharmacokinetics of amikacin in patients with normal or impaired renal function: radioenzymatic acetylation assay. J Infect Dis 1976; 134(suppl): 323-330.
30. Pieper JA, Vidal RA, Schentag JJ. Animal model distinguishing in vitro from in vivo carbenicillin-aminoglycoside interactions. Antimicrob Agents Chemother 1980; 18: 604-609.
31. Kradjan WA, Burger R. In vivo inactivation of gentamicin by carbenicillin and ticarcillin. Arch Intern Med 1980; 140: 1668-1670.
32. Ellis PP, Rendi MA. Inactivation of aminoglycoside-penicillin combinations after subconjunctival injection. Can J Ophthalmol 1981; 16: 79-83.
33. Konishi H, Goto M, Nakamoto Y, Yamamoto I, Yamashina H. Tobramycin inactivation by carbenicillin, ticarcillin, and piperacillin. Antimicrob Agents Chemother 1983; 23: 653-657.
34. Blair DC, Duggan DO, Schroeder ET. Inactivation of amikacin and gentamicin by carbenicillin in patients with end-stage renal failure. Antimicrob Agents Chemother 1982; 22: 376-379.
35. Aronoff GR, Brier ME, Nierste DM, Sloan RS. Interactions of moxalactam and tobramycin in normal volunteers and in patients with impaired renal function. J Infect Dis 1984; 149: 9-15.
36. Warren JW, Miller EH, Fitapatrick B et al. A randomized controlled trial of cefoperazone vs. cefamandole-tobramycin in the treatment of putative severe infections with Gram-negative bacilli. Rev Infect Dis 1983; 5: 173-180.
37. Hooker KD, DiPiro JT, Wynn JJ. Aminoglycoside combinations versus beta-lactams alone for penetrating abdominal trauma: a meta-analysis. J Trauma 1991; 31: 1155-1160.
38. Cometta A, Baumgartner JD, Lew D et al. Prospective randomized comparison of imipenem monotherapy with imipenem plus netilmicin for treatment of severe infections in nonneutropenic patients. Antimicrob Agents Chemother 1994; 38: 1309-1313.